{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for m root_names_name in Any Name (approximate match)
Status:
Possibly Marketed Outside US
Source:
Zithranol by Elorac Inc.
(2012)
Source URL:
First approved in 2012
Source:
Zithranol by Elorac Inc.
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
21 CFR 350
(2023)
Source URL:
First approved in 2008
Source:
21 CFR 352
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
21 CFR 346
(2003)
Source URL:
First approved in 1996
Source:
21 CFR 352
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
21 CFR 333E
(1998)
Source URL:
First approved in 1995
Source:
21 CFR 333E
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
21 CFR 333A
(2015)
Source URL:
First approved in 1993
Source:
21 CFR 358H
Source URL:
Class:
MIXTURE
Status:
US Approved Rx
(2022)
Source:
BLA761263
(2022)
Source URL:
First approved in 2022
Source:
BLA761263
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2021)
Source:
BLA761195
(2021)
Source URL:
First approved in 2021
Source:
BLA761195
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2021)
Source:
NDA214231
(2021)
Source URL:
First approved in 2021
Source:
NDA214231
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2005)
Source:
BLA125118
(2005)
Source URL:
First approved in 2005
Source:
BLA125118
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2004)
Source:
NDA021060
(2004)
Source URL:
First approved in 2004
Source:
NDA021060
Source URL:
Class:
PROTEIN
Conditions:
Ziconotide (PRIALT; SNX-111) is a neuroactive peptide, which was approved by FDA in 2004 for the management of severe chronic pain in adult patients for whom intrathecal therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies, or intrathecal morphine. Ziconotide acts as a selective N-type voltage-gated calcium channel blocker, which leads to a blockade of excitatory neurotransmitter release from the primary afferent nerve terminals.
